Al­co­bra blast­ed by a PhI­II flop for AD­HD drug as its op­tions dwin­dle

You can turn out the lights at Al­co­bra. The par­ty is over, and it end­ed bad­ly.

This morn­ing the Is­raeli biotech $AD­HD re­vealed that its Phase III study of MDX flopped. The drug failed to dis­tin­guish it­self from a place­bo, and the com­pa­ny will now start con­sid­er­ing the strate­gic op­tions left to it as a re­sult.

There won’t be many op­tions to choose from. MDX was its on­ly drug in the clin­ic and in a con­fer­ence call with in­vestors ex­ecs told an­a­lysts that they are end­ing work on the pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.